The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020
Open accessAbstract
Comprehensive guidelines for treatment of latent tuberculosis infection (LTBI) among persons living in the United States were last published in 2000 (American Thoracic Society. CDC targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000;161:S221-47). Since then, several new regimens have been evaluated in clinical trials. To update previous guidelines, the National Tuberculosis Controllers Association (NTCA) and CDC convened a committee to conduct a systematic literature review and make new recommendations for the most effective and least toxic regimens for treatment of LTBI among persons who live in the United States.The systematic literature review included clinical trials of regimens to treat LTBI. Quality of evidence (high, moderate, low, or very low) from clinical trial comparisons was appraised using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) criteria. In addition, a network meta-analysis evaluated regimens that had not been compared directly in clinical trials. The effectiveness outcome was tuberculosis disease; the toxicity outcome was hepatotoxicity. Strong GRADE recommendations required at least moderate evidence of effectiveness and that the desirable consequences outweighed the undesirable consequences in the majority of patients. Conditional GRADE recommendations were made when determination of whether desirable consequences outweighed undesirable consequences was uncertain (e.g., with low-quality evidence).These updated 2020 LTBI treatment guidelines include the NTCA- and CDC-recommended treatment regimens that comprise three preferred rifamycin-based regimens and two alternative monotherapy regimens with daily isoniazid. All recommended treatment regimens are intended for persons infected with Mycobacterium tuberculosis that is presumed to be susceptible to isoniazid or rifampin. These updated guidelines do not apply when evidence is available that the infecting M. tuberculosis strain is resistant to both isoniazid and rifampin; recommendations for treating contacts exposed to multidrug-resistant tuberculosis were published in 2019 (Nahid P, Mase SR Migliori GB, et al. Treatment of drug-resistant tuberculosis. An official ATS/CDC/ERS/IDSA clinical practice guideline. Am J Respir Crit Care Med 2019;200:e93-e142). The three rifamycin-based preferred regimens are 3 months of once-weekly isoniazid plus rifapentine, 4 months of daily rifampin, or 3 months of daily isoniazid plus rifampin. Prescribing providers or pharmacists who are unfamiliar with rifampin and rifapentine might confuse the two drugs. They are not interchangeable, and caution should be taken to ensure that patients receive the correct medication for the intended regimen. Preference for these rifamycin-based regimens was made on the basis of effectiveness, safety, and high treatment completion rates. The two alternative treatment regimens are daily isoniazid for 6 or 9 months; isoniazid monotherapy is efficacious but has higher toxicity risk and lower treatment completion rates than shorter rifamycin-based regimens.In summary, short-course (3- to 4-month) rifamycin-based treatment regimens are preferred over longer-course (6-9 month) isoniazid monotherapy for treatment of LTBI. These updated guidelines can be used by clinicians, public health officials, policymakers, health care organizations, and other state and local stakeholders who might need to adapt them to fit individual clinical circumstances.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The recommended treatment for latent TB has recently changed from 6 to 9 months of isoniazid monotherapy to regimens with a lower risk of hepatoxicity, including 3–4‐month regimens of isoniazid with other agents.185”
From AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury (2023) · cites this paper as [185]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Dermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,451
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
Conducting Meta-Analyses in R with the metafor Package
Viechtbauer, W. (2010) · Journal of Statistical Software · doi:10.18637/jss.v036.i03 · Cited by 20,464
The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling
Houben, R. M. G. J., & Dodd, P. J. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1002152 · Cited by 2,054
Andrews, J., Guyatt, G., Oxman, A. D., Alderson, P., Dahm, P., Falck-Ytter, Y., Nasser, M., Meerpohl, J., Post, P. N., Kunz, R., et al. (2013) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2012.03.013 · Cited by 1,416
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa
The TEMPRANO ANRS 12136 Study Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507198 · Cited by 1,242
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.supplement_3.ats600 · Cited by 1,241
Three Months of Rifapentine and Isoniazid for Latent Tuberculosis Infection
Sterling, T. R., Villarino, M. E., Borisov, A. S., Shang, N., Gordin, F., Bliven-Sizemore, E., Hackman, J., Hamilton, C. D., Menzies, D., Kerrigan, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104875 · Cited by 977
Self-citationControlled chemoprophylaxis trials in tuberculosis. A general review.
Sh, F. (1970) · PubMed · Cited by 721
Dias, S., Welton, N. J., Sutton, A. J., & Ades, A. E. (2011) · Bristol Research (University of Bristol) · Cited by 553
Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection
Pape, J. W., Jean, S. S., Ho, J. L., Hafner, A., & Johnson, W. D. (1993) · The Lancet · doi:10.1016/0140-6736(93)91817-6 · Cited by 441
Toxic Hepatitis with Isoniazid and Rifampin
Steele, M. A., Burk, R. F., & DesPrez, R. M. (1991) · Chest · doi:10.1378/chest.99.2.465 · Cited by 437
Whalen, C. C., Johnson, J. L., Okwera, A., Hom, D. L., Huebner, R., Mugyenyi, P., Mugerwa, R. D., Ellner, J. J., Nsubuga, P., Vjecha, M., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709183371201 · Cited by 396
New Regimens to Prevent Tuberculosis in Adults with HIV Infection
Martinson, N. A., Barnes, G. L., Moulton, L. H., Msandiwa, R., Hausler, H., Ram, M., McIntyre, J. A., Gray, G. E., & Chaisson, R. E. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1005136 · Cited by 385
Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults
Menzies, D., Adjobimey, M., Ruslami, R., Trajman, A., Sow, O., Kim, H., Obeng Baah, J., Marks, G. B., Long, R., Hoeppner, V., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714283 · Cited by 383
Self-citationOne Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis
Swindells, S., Ramchandani, R., Gupta, A., Benson, C. A., Leon-Cruz, J., Mwelase, N., Jean Juste, M. A., Lama, J. R., Valencia, J., Omoz-Oarhe, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1806808 · Cited by 363
Samandari, T., Agizew, T. B., Nyirenda, S., Tedla, Z., Sibanda, T., Shang, N., Mosimaneotsile, B., Motsamai, O. I., Bozeman, L., Davis, M. K., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60204-3 · Cited by 355
Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics
Abu-Raddad, L. J., Sabatelli, L., Achterberg, J. T., Sugimoto, J. D., Longini, I. M., Dye, C., & Halloran, M. E. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0901720106 · Cited by 348
Hong Kong Chest Service/Tuberculosis Research Centre, M. M. R. C. (1992) · American Review of Respiratory Disease · doi:10.1164/ajrccm/145.1.36 · Cited by 304
Halsey, N. A., Coberly, J. S., Desormeaux, J., Losikoff, P., Atkinson, J., Moulton, L. H., Contave, M., Johnson, M., Davis, H., Geiter, L., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(97)06532-x · Cited by 270
How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?
Moulding, T. (2000) · PubMed · Cited by 268
Rangaka, M. X., Wilkinson, R. J., Boulle, A., Glynn, J. R., Fielding, K., van Cutsem, G., Wilkinson, K. A., Goliath, R., Mathee, S., Goemaere, E., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60162-8 · Cited by 262
Spyridis, N. P., Spyridis, P. G., Gelesme, A., Sypsa, V., Valianatou, M., Metsou, F., Gourgiotis, D., & Tsolia, M. N. (2007) · Clinical Infectious Diseases · doi:10.1086/520983 · Cited by 259
Zar, H. J., Cotton, M. F., Strauss, S., Karpakis, J., Hussey, G., Schaaf, H. S., Rabie, H., & Lombard, C. J. (2007) · BMJ · doi:10.1136/bmj.39000.486400.55 · Cited by 254
Isoniazid prophylaxis among Alaskan Eskimos: a final report of the bethel isoniazid studies.
Comstock, G. W., Baum, C., & Snider, D. E. (1979) · PubMed · doi:10.1164/arrd.1979.119.5.827 · Cited by 241
(1982) · Europe PMC (PubMed Central) · Cited by 236
How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?
Gw, C. (1999) · PubMed · Cited by 233
Villarino, M. E., Scott, N. A., Weis, S. E., Weiner, M., Conde, M. B., Jones, B., Nachman, S., Oliveira, R., Moro, R. N., Shang, N., et al. (2015) · JAMA Pediatrics · doi:10.1001/jamapediatrics.2014.3158 · Cited by 226
Self-citationLatent TB Infection Treatment Acceptance and Completion in the United States and Canada
Horsburgh, C. R., Goldberg, S., Bethel, J., Chen, S., Colson, P. W., Hirsch-Moverman, Y., Hughes, S., Shrestha-Kuwahara, R., Sterling, T. R., Wall, K., et al. (2010) · Chest · doi:10.1378/chest.09-0394 · Cited by 224
Self-citationEna, J., & Valls, V. (2005) · Clinical Infectious Diseases · doi:10.1086/427802 · Cited by 217
Treatment of Latent Tuberculosis Infection: An Updated Network Meta-analysis
Zenner, D., Beer, N., Harris, R. J., Lipman, M. C., Stagg, H. R., & van der Werf, M. J. (2017) · Annals of Internal Medicine · doi:10.7326/m17-0609 · Cited by 214
Self-citationA controlled trial of community-wide isoniazid prophylaxis in Alaska.
Comstock, G. W., Ferebee, S. H., & Hammes, L. M. (1967) · PubMed · doi:10.1164/arrd.1967.95.6.935 · Cited by 211
Sutherland, I. (1976) · PubMed · Cited by 210
Mtei, L., Matee, M., Herfort, O., Bakari, M., Horsburgh, C. R., Waddell, R., Cole, B. F., Vuola, J. M., Tvaroha, S., Kreiswirth, B., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/429825 · Cited by 189
Self-citationFerebee, S. H., & MOUNT, F. W. (1962) · PubMed · doi:10.1164/arrd.1962.85.4.490 · Cited by 187
Menzies, D., Long, R., Trajman, A., Dion, M.-J., Yang, J., Al Jahdali, H., Memish, Z., Khan, K., Gardam, M., Hoeppner, V., et al. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-149-10-200811180-00003 · Cited by 187
Self-citationUpdate on rifampin, rifabutin, and rifapentine drug interactions
Baciewicz, A. M., Chrisman, C. R., Finch, C. K., & Self, T. H. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.747952 · Cited by 178
Menzies, D., Dion, M.-J., Rabinovitch, B., Mannix, S., Brassard, P., & Schwartzman, K. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200404-478oc · Cited by 168
Self-citationGordin, F. M., Matts, J. P., Miller, C., Brown, L. S., Hafner, R., John, S. L., Klein, M., Vaughn, A., Besch, C. L., Perez, G., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707313370505 · Cited by 166
Sterling, T. R., Scott, N. A., Miro, J. M., Calvet, G., La Rosa, A., Infante, R., Chen, M. P., Benator, D. A., Gordin, F., Benson, C. A., et al. (2016) · AIDS · doi:10.1097/qad.0000000000001098 · Cited by 165
Self-citationSafety and Side Effects of Rifampin versus Isoniazid in Children
Diallo, T., Adjobimey, M., Ruslami, R., Trajman, A., Sow, O., Obeng Baah, J., Marks, G. B., Long, R., Elwood, K., Zielinski, D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714284 · Cited by 165
Self-citationMiramontes, R., Hill, A. N., Yelk Woodruff, R. S., Lambert, L. A., Navin, T. R., Castro, K. G., & LoBue, P. A. (2015) · PLOS ONE · doi:10.1371/journal.pone.0140881 · Cited by 163
Self-citationBelknap, R., Holland, D., Feng, P.-J., Millet, J.-P., Caylà, J. A., Martinson, N. A., Wright, A., Chen, M. P., Moro, R. N., Scott, N. A., et al. (2017) · Annals of Internal Medicine · doi:10.7326/m17-1150 · Cited by 163
Self-citationTreatment of Latent Tuberculosis Infection: A Network Meta-analysis
Stagg, H. R., Zenner, D., Harris, R. J., Muñoz, L., Lipman, M. C., & Abubakar, I. (2014) · Annals of Internal Medicine · doi:10.7326/m14-1019 · Cited by 162
Self-citationPrimary Isoniazid Prophylaxis against Tuberculosis in HIV-Exposed Children
Madhi, S. A., Nachman, S., Violari, A., Kim, S., Cotton, M. F., Bobat, R., Jean-Philippe, P., McSherry, G., & Mitchell, C. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011214 · Cited by 161
Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults
Johnson, J. L., Okwera, A., Hom, D. L., Mayanja‐Kizza, H., Kityo, C. M., Nsubuga, P., Nakibali, J. G., Loughlin, A. M., Yun, H. W., Mugyenyi, P. N., et al. (2001) · AIDS · doi:10.1097/00002030-200111090-00009 · Cited by 161
Transmission of Tuberculosis to Close Contacts of Patients With Multidrug-Resistant Tuberculosis
Kritski, A. L., Marques, M. J., Rabahi, M. F., Vieira, M. A. M. S., Werneck-Barroso, E., Carvalho, C. E., Andrade, G. D. N., Bravo-de-Souza, R., Andrade, L. M., Gontijo, P. P., et al. (1996) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.153.1.8542139 · Cited by 144
Schechter, M., Zajdenverg, R., Falco, G., Barnes, G. L., Faulhaber, J. C., Coberly, J. S., Moore, R. D., & Chaisson, R. E. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200512-1953oc · Cited by 144
Isoniazid preventive therapy for tuberculosis in HIV-1-infected adults
Hawken, M. P., Meme, H., Elliott, L. C., et al. (1997) · AIDS · doi:10.1097/00002030-199707000-00006 · Cited by 141
Williamson, B., Dooley, K. E., Zhang, Y., Back, D. J., & Owen, A. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01124-13 · Cited by 138
Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults
QUIGLEY, M. A., Mwinga, A., Kitchen, M., Lisse, I. M., Fuchs, D., Porter, J. D. H., & Godfrey‐Faussett, P. (2001) · AIDS · doi:10.1097/00002030-200101260-00011 · Cited by 131
Sterling, T. R., Moro, R. N., Borisov, A. S., Phillips, E., Shepherd, G. M., Adkinson, N. F., Weis, S. E., Ho, C., & Villarino, M. E. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ323 · Cited by 113
Self-citationA controlled trial of isoniazid prophylaxis in mental institutions
Ferebee, S. H., MOUNT, F. W., Murray, F. J., & Livesay, V. T. (1964) · Nursing Research · doi:10.1097/00006199-196401320-00046 · Cited by 91
Prospective randomized control trial of isoniazid chemoprophylaxis during renal replacement therapy
Vikrant, S., Agarwal, S. K., Gupta, S. K., Bhowmik, D. M., Tiwari, S. C., Dash, S., Guleria, S., & Mehta, S. (2005) · Transplant Infectious Disease · doi:10.1111/j.1399-3062.2005.00103.x · Cited by 87
John, G. T., Thomas, P. P., Thomas, M., Jeyaseelan, L., Jacob, C. K., & Shastry, J. C. M. (1994) · PubMed · Cited by 78
John, G. T., Thomas, P. P., Thomas, M., Jeyaseelan, L., Jacob, C. K., & Shastry, J. C. M. (1994) · Transplantation · doi:10.1097/00007890-199457110-00029 · Cited by 78
Prospective randomised trial of isoniazid prophylaxis in renal transplant recipient
Agarwal, S. K., Gupta, S. K., Dash, S., Bhowmik, D. M., & Tiwari, S. C. (2004) · International Urology and Nephrology · doi:10.1007/s11255-004-6251-6 · Cited by 70
Gordin, F. M., Cohn, D. L., Matts, J. P., Chaisson, R. E., & Brien, R. J. O. (2004) · Clinical Infectious Diseases · doi:10.1086/422724 · Cited by 64
Self-citationTuberculosis incidence after 36 months’ isoniazid prophylaxis in HIV-infected adults in Botswana
Samandari, T., Agizew, T., Nyirenda, S., Tedla, Z., Sibanda, T., Mosimaneotsile, B., Motsamai, O. I., Shang, N., Rose, C. E., & Shepherd, J. (2014) · AIDS · doi:10.1097/qad.0000000000000535 · Cited by 50
Use of isoniazid chemoprophylaxis in renal transplant recipients
Naqvi, R., Naqvi, A., Akhtar, S., Ahmed, E., Noor, H., Saeed, T., Akhtar, F., & Rizvi, A. (2009) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp489 · Cited by 49
Gj, V. (1968) · PubMed · Cited by 46
Epidemiological basis of tuberculosis eradication. 4. The isoniazid trial in Greenland.
HORWITZ, O., Pg, P., & Wilbek, E. (1966) · PubMed · Cited by 46
Leung, C. C., Law, W. S., Chang, K. C., Tam, C. M., Yew, W. W., Chan, C. K., & Wong, M. (2003) · CHEST Journal · doi:10.1378/chest.124.6.2112 · Cited by 43
Cowie, R. L. (1996) · Tubercle and Lung Disease · doi:10.1016/s0962-8479(96)90007-6 · Cited by 34
Debre, R., Perdrizet, S., Lötte, A., NAVEAU, M., & Lert, F. (1973) · International Journal of Epidemiology · doi:10.1093/ije/2.2.153 · Cited by 34
Isoniazid vs. Rifampin for Latent Tuberculosis Infection in Jail Inmates: Toxicity and Adherence
White, M. C., Tulsky, J. P., Lee, J. R.-J., Chen, L., Goldenson, J., Spetz, J., & Kawamura, L. M. (2012) · Journal of Correctional Health Care · doi:10.1177/1078345811435973 · Cited by 29
MCMC convergence diagnosis via multivariate bounds on log-concave densities
Brooks, S. P. (1998) · The Annals of Statistics · doi:10.1214/aos/1030563991 · Cited by 28
Portilla, J., Jorda, P. L., Esteban, J., Sánchez–Payá, J., Merino, E., Boix, V., & Protocolo-INH, G. D. E. (2003) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/s0213-005x(03)72943-7 · Cited by 16
Cited by
Anti-tuberculosis treatment strategies and drug development: challenges and priorities
Dartois, V. A., & Rubin, E. J. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00731-y · Cited by 490
AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury
Fontana, R. J., Liou, I., Reuben, A., Suzuki, A., Fiel, M. I., Lee, W., & Navarro, V. (2023) · Hepatology · doi:10.1002/hep.32689 · Cited by 340
Metadata
- Authors
- Sterling, T. R., Njie, G., Zenner, D., Cohn, D. L., Reves, R., Ahmed, A., Menzies, D., Horsburgh, C. R., Crane, C. M., Burgos, M., LoBue, P., Winston, C. A., & Belknap, R.
- Venue
- MMWR. Recommendations and Reports
- Published
- 2020-02-14
- Volume
- 69
- Issue
- 1
- Pages
- 1-11
- ISSN
- 1057-5987 (ISSN-L)
- 1545-8601
- OpenAlex
- W3006339989
- Cited by
- 495
- References
- 71
- FWCI
- 8.45
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.